Sarah leonard
Chief Executive Officer T-Cypher Bio
Sarah helped to establish T-Cypher and is an experienced immunotherapy scientist with a track record of advancing novel T cell therapeutics from concept to clinic. Before joining T-Cypher, she was Scientist in Residence at Oxford Science Enterprises, creating innovative life science ventures. Prior to this Sarah was at Immunocore where she led a team of scientists to generate novel donor-unrestricted T cell therapeutics against oncology and infectious disease targets. She was also involved in the successful delivery of an HBV-bispecific to clinical trials for the treatment of chronic Hepatitis B. Prior to Immunocore, Sarah held a Translational Research Fellowship with Ovacome at the University of Birmingham, where she worked on novel drugs and biomarkers to predict disease progression and chemo resistance in cancer patients. She has also held a number of post-doctoral positions, including with Janssen Pharmaceuticals where she delivered the pre-clinical package for an epigenetic drug combination that went into an acute myeloid leukaemia clinical trial.
Seminars
- Demonstrating large-scale T-cell receptor discovery capability using a proprietary platform that identified hundreds of thousands of TCRs recognising previously uncharacterised antigens
- Validating the discovery-to-development bispecific pipeline by advancing a therapeutic program based on a novel, internally identified target that is distinct from existing programs
- Extending the platform beyond oncology into autoimmune disease by applying the same discovery engine to identify bispecific targets across multiple therapeutic indications
